Reardon DA, et al. - A phase 2 and biomarker study was planned to investigate trebananib, an angiopoietin 1 and angiopoietin 2 blocking peptibody, with and without bevacizumab in patients with recurrent glioblastoma. In this work, angiopoietin 1 and angiopoietin 2 inhibition with trebananib proved ineffective as monotherapy and did not improve the ability of vascular endothelial growth factor blockade with bevacizumab to improve the outcomes of these patients.